Recently, an investor inquired on an investor platform about the nicotine purity of Rundu Corporation (002923), the company's compliance with medical standards, as well as their nicotine production and primary customer base.
Rundu International responds to investors: Currently, Rundu International offers customized production based on customer needs, providing different purity levels of nicotine for various sectors including pharmaceuticals, pesticides, e-cigarettes, lozenges, and nicotine patches. The designed production capacity for the company's alkaloid (nicotine) project is 100 tons/year for plant extraction and purification processes, and 400 tons/year for chemical synthesis processes of alkaloids and intermediate products. The existing capacity is sufficient to meet sales demands. The company is actively exploring markets and adjusting production plans in a timely manner in accordance with local market access mechanisms.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
